Fundz

Priothera Appoints Jens Hasskarl as Chief Medical Officer

PRIVATEMay 06, 2025

Position

Chief Medical Officer

Company

Priothera

Jens Hasskarl
jens.hasskarl@priothera.com
Saint-LouisBiotechnologyHealth CareTherapeuticsBiopharma

Description

Priothera Ltd. has announced the appointment of Dr. Jens Hasskarl as Chief Medical Officer

Quick answer

Priothera Appoints Jens Hasskarl as Chief Medical Officer (May 6, 2025). Priothera is based in Saint-Louis, Grand Est, France.

Who is the new Chief Medical Officer at Priothera?
Priothera named Jens Hasskarl Chief Medical Officer, announced May 6, 2025.
What did Priothera announce on May 6, 2025?
Priothera Ltd. has announced the appointment of Dr. Jens Hasskarl as Chief Medical Officer
What does Priothera do?
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers.
Where is Priothera based?
Priothera is based in Saint-Louis, Grand Est, France.
Which similar companies made leadership changes around the same time?
BioNTech (May 5, 2025), Eccogene (May 1, 2025), Hansa Biopharma (May 13, 2025) and Avadel (May 13, 2025) also announced leadership changes within 45 days of Priothera.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biopharma

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Priothera, and when

A new leader at Priothera brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Priothera raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Priothera, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Priothera. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Priothera

Location

Saint-Louis, Grand Est, France

About

Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers. The company focuses on adjunctive and maintenance therapy for hematological malignancies, particularly acute myeloid leukemia (AML). They aim to improve patients’ quality of life and outcomes with innovative treatments.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Priothera changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Jens
Likely contact at this company
••••••••@••••••••

See Jens's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Priothera's next move

Learn about Strategic plan

Priothera changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.